V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015080 | 160016061 | 1.5 | 112 | null | 2016-09-28 | 2016-11-10 | Cisplatin + Pemetrexed | null | null | CISPLATIN + PEMETREXED | 100251077 |
| 160015083 | 160016062 | 1.6 | 63.95 | null | 2017-12-01 | 2018-05-04 | Doxorubicin + Olaratumab | N | N | DOXORUBICIN + OLARATUMAB | 100392719 |
| 160015085 | 160016063 | 1.72 | 70.8 | Palliative (P) | 2019-05-16 | 2019-05-17 | Bevacizumab 7.5mg/kg | 02 | null | BEVACIZUMAB | 101545033 |
| 160015090 | 160016064 | 1.51 | 176.2 | Palliative (P) | 2017-08-01 | 2017-09-18 | Bevacizumab 7.5mg/kg | 02 | N | BEVACIZUMAB | 100013059 |
| 160015091 | 160016065 | 1.79 | 62.4 | Palliative (P) | 2016-10-10 | 2016-10-17 | Bevacizumab 7.5mg/kg | 02 | N | BEVACIZUMAB | 100361432 |
| 160015092 | 160016066 | 1.74 | 64.8 | Palliative (P) | 2020-04-14 | 2020-04-18 | Docetaxel + Gemcitabine with GCSF | 02 | N | DOCETAXEL + GEMCITABINE | 100398825 |
| 160015100 | 160016067 | 1.78 | 47.7 | Palliative (P) | 2020-01-24 | 2020-02-10 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101084023 |
| 160015103 | 160016068 | 1.71 | 64 | Palliative (P) | 2017-04-13 | 2017-07-18 | PACLITAXEL | 02 | N | PACLITAXEL | 100218320 |
| 160015109 | 160016069 | 1.88 | 70 | Disease modification (D) | 2019-08-18 | 2019-10-06 | Bevacizumab 7.5mg/kg | 02 | N | PACLITAXEL | 101838683 |
| 160015112 | 160016070 | 1.54 | 66.2 | Palliative (P) | 2021-05-15 | 2021-06-06 | CARBOPLATIN | 02 | N | CARBOPLATIN | 100910075 |
| 160015117 | 160016071 | 1.75 | 81 | Adjuvant (A) | 2016-11-28 | 2016-11-29 | Doxorubicin + Olaratumab | N | N | DOXORUBICIN + OLARATUMAB | 101705982 |
| 160015119 | 160016072 | 1.67 | 46.6 | Palliative (P) | 2018-04-11 | 2018-05-29 | Bevacizumab 7.5mg/kg | 02 | N | LIPOSOMAL DOXORUBICIN | 101564654 |
| 160015120 | 160016073 | 1.74 | 67.5 | null | 2017-04-08 | 2017-05-06 | Bevacizumab 7.5mg/kg | 02 | null | PACLITAXEL | 100988894 |
| 160015125 | 160016074 | 1.82 | null | null | 2019-04-03 | 2019-10-22 | null | null | null | OLARATUMAB | 101461802 |
| 160015137 | 160016075 | 1.71 | 61 | 03 | 2019-04-25 | 2019-04-25 | EW EuroEwing 2012 Arm A VAC | 02 | N | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101854820 |
| 160015139 | 160016076 | 1.56 | 19.1 | Palliative (P) | 2019-02-13 | 2019-02-21 | STS Rhabdomyosarcoma RMS 2005 IVADo | N | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 101142357 |
| 160015144 | 160016077 | 1.95 | 62.6 | Palliative (P) | 2019-08-10 | 2019-08-17 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | null | TRIAL | 101787897 |
| 160015146 | 160016078 | 1.62 | 76.2 | Curative (C) | 2021-02-11 | 2021-02-19 | FLUOROURACIL + IRINOTECAN | 01 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 100154359 |
| 160015147 | 160016079 | 1.63 | 82.2 | Adjuvant (A) | 2019-09-20 | 2019-10-25 | MELPHALAN | 01 | N | TRIAL | 101445670 |
| 160015152 | 160016080 | 1.62 | 54 | null | 2020-08-10 | 2021-04-25 | Niraparib | null | null | NIRAPARIB | 100129396 |
| 160015165 | 160016082 | 0 | 47.7 | Curative (C) | 2019-06-18 | 2019-07-09 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101793642 |
| 160015167 | 160016083 | 1.56 | 60.2 | Curative (C) | 2018-04-11 | 2018-08-23 | Ifosfamide | 2 | Y | OLAPARIB | 100548178 |
| 160015171 | 160016085 | 1.19 | 63.9 | null | 2017-01-25 | 2017-02-15 | AFATINIB | null | null | CAPECITABINE + TEMOZOLOMIDE | 100713044 |
| 160015183 | 160016086 | 0 | 78.5 | 03 | 2019-12-15 | 2020-07-02 | Ifosfamide | 02 | N | GEMCITABINE + TREOSULFAN | 100204205 |
| 160015190 | 160016087 | 1.65 | 67.6 | 03 | 2018-11-27 | 2019-01-02 | PROMISE-MESO TRIAL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101594427 |
| 160015194 | 160016088 | 1.56 | 19.25 | null | 2019-06-17 | 2019-06-17 | IVA | 02 | null | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 100725628 |
| 160015196 | 160016089 | null | null | null | 2019-03-01 | 2019-03-19 | BUSULFAN + MELPHALAN | null | null | OLARATUMAB | 101212714 |
| 160015197 | 160016090 | 1.82 | 16.4 | Adjuvant (A) | 2018-12-30 | 2019-01-03 | Doxorubicin + Ifosfamide | N | Y | GEMCITABINE | 100515661 |
| 160015200 | 160016091 | 1.68 | 74 | null | 2020-11-09 | 2020-11-15 | VAC | 02 | null | CYTARABINE | 101413559 |
| 160015220 | 160016092 | 1.06 | 49.2 | null | 2021-10-13 | 2021-10-22 | NB HRNBL-1 Isotretinoin | null | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100471190 |
| 160015226 | 160016093 | 1.68 | 71 | Curative (C) | 2018-11-17 | 2019-01-21 | Trial Unspecified | 01 | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101829245 |
| 160015227 | 160016094 | 0 | 52.6 | Curative (C) | 2019-09-07 | 2019-10-11 | Doxorubicin + Ifosfamide | 02 | N | OLARATUMAB | 100290502 |
| 160015228 | 160016095 | 0 | 0 | null | 2020-08-05 | 2020-09-04 | Doxorubicin + Ifosfamide | null | null | CISPLATIN + VINORELBINE | 101156994 |
| 160015237 | 160016096 | 1.66 | 38.1 | null | 2019-05-26 | 2019-05-26 | PROMISE-MESO TRIAL | null | null | GEMCITABINE | 100276483 |
| 160015242 | 160016097 | null | 105.6 | Curative (C) | 2013-09-03 | 2017-04-15 | Ifosfamide | 02 | N | NOT MATCHED | 101231906 |
| 160015246 | 160016098 | 1.8 | 3.9 | Neo-adjuvant (N) | 2017-03-10 | 2017-04-12 | Doxorubicin + Ifosfamide | 02 | N | NIRAPARIB | 100480427 |
| 160015257 | 160016099 | 0 | 14 | Palliative (P) | 2020-08-03 | 2020-10-08 | Rucaparib | 02 | N | IVA | 101097484 |
| 160015260 | 160016100 | 1.15 | 76.8 | Curative (C) | 2017-06-10 | 2017-11-30 | Niraparib | 02 | N | NOT MATCHED | 101303695 |
| 160015261 | 160016101 | 1.68 | 17.6 | Palliative (P) | 2016-07-30 | 2016-10-03 | Gemcitabine + Treosulfan (iv) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101529405 |
| 160015272 | 160016102 | 1.66 | 114.6 | Curative (C) | null | 2020-05-31 | Ifosfamide | 02 | N | GEMCITABINE | 101150154 |
| 160015278 | 160016103 | 1.91 | 79 | null | 2017-01-19 | 2017-02-23 | VAC | 02 | null | VINCRISTINE | 100252141 |
| 160015281 | 160016104 | 1.45 | 110 | Palliative (P) | 2017-04-16 | 2017-04-21 | Ifosfamide | 02 | N | IFOSFAMIDE | 101769600 |
| 160015283 | 160016105 | 1.64 | 78.4 | null | 2016-12-28 | 2017-02-08 | Doxorubicin + Ifosfamide | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100680864 |
| 160015290 | 160016106 | 1.86 | 14.1 | Disease modification (D) | 2016-12-21 | 2017-03-10 | EW EuroEwing 2012 Arm B IE | 02 | Y | IVA | 101658935 |
| 160015293 | 160016107 | 1.63 | 17.5 | Palliative (P) | 2018-10-15 | 2019-02-04 | LANREOTIDE | 02 | N | GEMCITABINE | 101863393 |
| 160015296 | 160016108 | null | 30.2 | null | 2016-11-01 | 2017-05-06 | ATOMIC-MESO TRIAL | 02 | null | TOPOTECAN | 100476192 |
| 160015301 | 160016109 | 1.5 | 114.6 | 03 | 2020-08-23 | 2020-08-23 | NB HRNBL-1 COJEC Ind COURSE C | 02 | null | IPILIMUMAB + NIVOLUMAB | 100376977 |
| 160015305 | 160016110 | 1.73 | 66 | Curative (C) | 2017-03-18 | 2017-03-18 | Rucaparib | 02 | Y | CONFIRM TRIAL | 100572495 |
| 160015306 | 160016111 | 1.79 | 67.4 | 03 | 2016-11-13 | 2016-12-17 | Doxorubicin + Ifosfamide | null | null | PROMISE-MESO TRIAL | 100439448 |
| 160015308 | 160016112 | 1.56 | 69 | Palliative (P) | 2021-10-19 | 2021-12-06 | CABOZANTINIB | 02 | N | CYCLOPHOSPHAMIDE | 101227183 |